Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia. Show more
Location: 650 Chapel Street, 650 Chapel St, South Yarra, VIC, 3141, Australia | Website: https://opthea.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
524.8M
52 Wk Range
$2.02 - $6.30
Previous Close
$3.41
Open
$3.41
Volume
N/A
Day Range
$3.41 - $3.41
Enterprise Value
4.289B
Cash
131.9M
Avg Qtr Burn
-39.45M
Insider Ownership
0.00%
Institutional Own.
5.06%
Qtr Updated
12/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OPT-302 Details Wet age-related macular degeneration , Eye disease | Failed Discontinued | |
OPT-302 Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |